What does this research mean for the field?

Approximately 1 in 25 patients treated with enzalutamide plus leuprolide for 9 months achieved sustained PSA <0.2 ng/mL and testosterone recovery 3 years post-therapy, indicating long-term remissions are possible with hormonal therapy only. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the proportion of prostate cancer patients achieving sustained PSA <0.2 ng/mL after hormonal therapy suspension despite testosterone recovery.

March 4, 2026

Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) <0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.

Q: What question did this study set out to answer?

To evaluate the proportion of prostate cancer patients achieving sustained PSA <0.2 ng/mL after hormonal therapy suspension despite testosterone recovery.

Puntos clave

To evaluate the proportion of prostate cancer patients achieving sustained PSA <0.2 ng/mL after hormonal therapy suspension despite testosterone recovery.
Post hoc analysis of the EMBARK trial data
Randomized patients to receive enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy
Assessed rates of PSA <0.2 ng/mL at 12, 24, and 36 months after treatment suspension.
9.3% of patients in the enza combo group maintained PSA <0.2 ng/mL after 36 months
1.4% and 1.1% of patients in the LA and enza mono groups maintained PSA <0.2 ng/mL, respectively
Indicates a higher long-term remission rate in patients treated with enza combo compared to other therapies.

Resumen

189 Background: The phase 3 EMBARK trial (NCT02319837) assessed enzalutamide plus leuprolide (enza combo), leuprolide alone (LA), and enzalutamide monotherapy (enza mono) in patients (pts) with prostate cancer and high-risk biochemical recurrence. EMBARK demonstrated significant improvements for metastasis-free survival (enza combo and enza mono) and overall survival (enza combo). A key feature of EMBARK was tx suspension after 37 weeks in pts with PSA 250 ng/dL. Results for T recovery to baseline and >175 ng/dL are shown (Table). Conclusions: Approximately 1 in 25 pts treated with enza combo for 9 months had PSA 175 ng/dL † , n (%) 72 (20.4) 33 (9.3) 29 (8.2) 35 (9.9) 17 (4.8) 12 (3.4) 15 (4.2) 8 (2.3) 5 (1.4) T >250 ng/dL ‡ , n (%) 44 (12.5) 21 (5.9) 23 (6.5) 25 (7.1) 15 (4.2) 10 (2.8) 13 (3.7) 5 (1.4) 4 (1.1) T ≥baseline § , n (%) 21 (5.9) 11 (3.1) 18 (5.1) 16 (4.5) 10 (2.8) 10 (2.8) 9 (2.5) 3 (0.8) 4 (1.1) No T assessment, n (%) 6 (1.7) 5 (1.4) 2 (0.6) 8 (2.3) 3 (0.8) <jats:td c

Me gusta

Guardar